Cargando…
2173. Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections
BACKGROUND: Ceftobiprole (BPR) is an advanced-generation cephalosporin that has in vitro and in vivo activity against clinically important Gram-positive organisms, including MRSA and Gram-negative organisms. While BPR does not have clinically relevant activity against Enterococcus faecium, BPR is ac...
Autores principales: | Mendes, Rodrigo E, Duncan, Leonard R, Sader, Helio S, Smart, Jennifer, Jones, Mark E, Castanheira, Mariana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677393/ http://dx.doi.org/10.1093/ofid/ofad500.1795 |
Ejemplares similares
-
Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017) -
2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023) -
1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020
por: Duncan, Leonard R, et al.
Publicado: (2021) -
Ampicillin and Ceftobiprole Combination for the Treatment of Enterococcus faecalis Invasive Infections: “The Times They Are A-Changin”
por: Giuliano, Simone, et al.
Publicado: (2023) -
1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)